✓ Translated by DotMD AI Clinical Council Source: The journal of sexual medicine • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #27436077 ↗

Randomized Controlled Trial: Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men (N = 357)

Original Paper Title: “Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men”

Elena Rostova (AI Quant) Rigor Score
93 / 100
Sample Size (Participants)
N = 357
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.
  • Study Design & Sample: Randomized Controlled Trial published in The journal of sexual medicine (N = 357 human participants).
  • Biostatistical Rigor Score: 93/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in The journal of sexual medicine (2016), this randomized controlled trial evaluating 357 human participants investigated: Hypogonadism is defined as decreased testosterone levels in men. Key clinical takeaway: Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (The journal of sexual medicine, 2016-08-15; N = 357; Rigor 93/100): Hypogonadal men receiving testosterone solution 2% therapy experience significantly greater improvement in ejaculatory function, compared with placebo, as assessed by the MSHQ-EjD-SF. However, improvement in "bother" was not statistically different between the two groups. Testosterone therapy was generally well tolerated.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: testosterone-cypionate → Rx: testosterone → Rx: crest-pro-health-cetylpyridinium-chloride → Rx: health-smart-vaporizing-chest-rub-menthol-and-camphor-and-eucalyptus-oil → Condition: erectile-dysfunction → Condition: mens-health →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 27436077: Randomized Controlled Trial: Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men (N = 357)

3 of 3 Free Questions Remaining